title: Bevacizumab-induced hand-foot syndrome: circumscribed type.
authors.forename: A
authors.initials: A
authors.lastname: Munehiro
authors.forename: K
authors.initials: K
authors.lastname: Yoneda
authors.forename: K
authors.initials: K
authors.lastname: Nakai
authors.forename: T
authors.initials: T
authors.lastname: Demitsu
authors.forename: T
authors.initials: T
authors.lastname: Moriue
authors.forename: J
authors.initials: J
authors.lastname: Moriue
authors.forename: I
authors.initials: I
authors.lastname: Yokoi
authors.forename: N
authors.initials: N
authors.lastname: Fujita
authors.forename: N
authors.initials: N
authors.lastname: Matsuura
authors.forename: S
authors.initials: S
authors.lastname: Ishikawa
authors.forename: H
authors.initials: H
authors.lastname: Yokomise
authors.forename: Y
authors.initials: Y
authors.lastname: Kubota
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001768:Blister / Q000139:chemically induced; D004890:Erythema / Q000139:chemically induced; D005260:Female; D005533:Foot Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006229:Hand Dermatoses / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab